Dong-A, GSK unable to agree on product swap

Published: 2011-07-13 06:59:00

Updated: 2011-07-13 06:59:00

Dong-A Pharmaceutical and GlaxoSmithKline (GSK), the world’s third largest pharmaceutical firm by revenue, are said to end their negotiations to exchange their healthcare products, such as Polident, Sensodyne and Garglin without agreement, according to market watchers.

So far, both companies h...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK